David Silbert, MD
Ophthalmology · Lancaster, PANPI 1275593295
Payments from drug & device makers
Across 80 payments — averaging $393.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$17K
- Kala Pharmaceuticals, Inc.$8K
- Novartis$5K
- Notal Vision, Inc.$246
- Alcon$206
- Tarsus Pharmaceuticals, Inc.$149
- plus $809 from 15 others
What the payments were for
- Consulting fees$450%
- Speaking & faculty fees$14,21176%
- Travel & lodging$2,15212%
- Food & beverage$2,22512%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $17,229 |
| Kala Pharmaceuticals, Inc. | 8 | $8,273 |
| Novartis | 3 | $4,540 |
| Notal Vision, Inc. | 1 | $246 |
| Alcon | 2 | $206 |
| Tarsus Pharmaceuticals, Inc. | 6 | $149 |
| Shire North American Group Inc | 1 | $120 |
| Carl Zeiss Meditec USA, Inc. | 1 | $103 |
| Organogenesis Inc. | 4 | $101 |
| Merz Pharmaceuticals, LLC | 5 | $96 |
| AbbVie(2 entities) | 3 | $90 |
| Ocular Therapeutix, Inc. | 3 | $77 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| Exact Sciences | 1 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| AstraZeneca | 1 | $27 |
| Biotissue Holdings Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$15,616
- Clareon$121
- XIIDRA$120
- CIRRUS HD-OCT$103
How this compares
$31,451 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZyletTobramycin/Lotepred Etab | 42 | $20,936 |
| ErythromycinErythromycin Base | 352 | $3,302 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 287 | $2,884 |
| Doxycycline Monohydrate | 108 | $2,851 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 78 | $2,796 |
| Epinastine Hcl | 42 | $2,267 |
| Bacitracin | 13 | $1,003 |
| Cephalexin | 206 | $874 |
| Doxycycline Hyclate | 40 | $665 |
| Cromolyn Sodium | 34 | $560 |
| Tranexamic Acid | 101 | $388 |
| Fluticasone Propionate | 32 | $268 |
| Methylprednisolone | 43 | $239 |
| Tramadol Hcl | 61 | $89 |
| Clindamycin Hcl | 26 | $25 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lancaster
- Bethany RommelLancaster$91K
- Nora SiegalLancaster$78K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.